These findings align with our hypothesis that constitutive JAK/STAT activation is independent of specific JAK/STAT mutations, making STAT3/STAT5 inhibition a promising target for T-PLL cases, irrespective of their JAK/STAT molecular profile. Here, STAT3 is linked to prolymphocytic leukemia.